Comparative Pharmacology
Head-to-head clinical analysis: AMBISOME versus BUTENAFINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBISOME versus BUTENAFINE HYDROCHLORIDE.
AMBISOME vs BUTENAFINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
None Documented
None Documented
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Category C
Category C
Antifungal
Antifungal